Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx,...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of LDX.AX is 0.10 and suggests 58% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d
Buy
Sell